Listed

Nautilus Biotechnology, Inc.

NAUTNasdaqCIK 1808805TechnologyFiscal year ends Dec 31

Latest reported revenue, Q3 FY2026$234.0kRevenue, Q3 FY2026, three months to 2026-09-30$234.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 27, 2026.

Latest quarter: Q3 FY2026

Three months to Sep 30, 2026, against the same quarter a year earlier.

  • Revenue$234.0kRevenue, Q3 FY2026, three months to 2026-09-30$234.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figureSign changed from a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating marginnot reported (Operating income not reported)No year-earlier figure to compare
  • Net margin−6682.1%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: −$15.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Revenue: $234.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figureNo year-earlier figure to compare
  • Diluted EPS−$0.12Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figure−9.1% on a year earlier
  • Free cash flow−$14.7mFree cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: −$13.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-27, accession 0001808805-26-000052. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-27, accession 0001808805-26-000052. Derived: 9-month figure less the 6-month figure.Report this figure−28.6% on a year earlier

Last eight quarters

Full statements
Revenue$234.0kNet margin −6682.1%
Diluted EPS−$0.12, Q3 FY2026
Free cash flow−$14.7m, Q3 FY2026
Nautilus Biotechnology, Inc., key figures for the last eight quarters
Line itemUnitQ4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-28, accession 0001808805-26-000034.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)0.2Revenue, Q2 FY2026, three months to 2026-06-30$190.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-28, accession 0001808805-26-000034.Report this figure0.2Revenue, Q3 FY2026, three months to 2026-09-30$234.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)not reported (Operating income not reported)not reported (Operating income not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)(7615.3%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$14.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-28, accession 0001808805-26-000034.Revenue: $190.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-28, accession 0001808805-26-000034.Report this figure(6682.1%)Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: −$15.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Revenue: $234.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(0.13)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-28, accession 0001808805-26-000022.Report this figure(0.12)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-28, accession 0001808805-26-000034.Report this figure(0.11)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figurenot reported (Diluted EPS not reported)(0.12)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-28, accession 0001808805-26-000022.Report this figure(0.11)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-28, accession 0001808805-26-000034.Report this figure(0.12)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-27, accession 0001808805-26-000052.Report this figure
Free cash flow$m(14.6)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001808805-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $254.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001808805-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(14.2)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$13.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-28, accession 0001808805-26-000022.Capital expenditure: $219.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-28, accession 0001808805-26-000022.Report this figure(13.7)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$13.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-28, accession 0001808805-26-000034. Derived: 6-month figure less the 3-month figure.Capital expenditure: $396.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-28, accession 0001808805-26-000034. Derived: 6-month figure less the 3-month figure.Report this figure(11.5)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-27, accession 0001808805-26-000052. Derived: 9-month figure less the 6-month figure.Capital expenditure: $418.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-27, accession 0001808805-26-000052. Derived: 9-month figure less the 6-month figure.Report this figure(12.6)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$12.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001808805-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $244.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001808805-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(13.6)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-28, accession 0001808805-26-000022.Capital expenditure: $510.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-28, accession 0001808805-26-000022.Report this figure(14.2)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$13.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-28, accession 0001808805-26-000034. Derived: 6-month figure less the 3-month figure.Capital expenditure: $454.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-28, accession 0001808805-26-000034. Derived: 6-month figure less the 3-month figure.Report this figure(14.7)Free cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: −$13.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-27, accession 0001808805-26-000052. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-27, accession 0001808805-26-000052. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Diluted EPS−$0.47, FY2025
Free cash flow−$52.0m, FY2025
Nautilus Biotechnology, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.60)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-02-23, accession 0001808805-23-000011.Report this figure(0.46)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-28, accession 0001808805-24-000005.Report this figure(0.51)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001808805-25-000008.Report this figure(0.56)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001808805-26-000011.Report this figure(0.47)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001808805-26-000011.Report this figure
Free cash flow$m(41.5)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$39.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-02-23, accession 0001808805-23-000011.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-02-23, accession 0001808805-23-000011.Report this figure(48.1)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$45.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-28, accession 0001808805-24-000005.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-28, accession 0001808805-24-000005.Report this figure(54.2)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$51.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001808805-25-000008.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001808805-25-000008.Report this figure(61.3)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$59.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001808805-26-000011.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001808805-26-000011.Report this figure(52.0)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$50.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001808805-26-000011.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001808805-26-000011.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Nautilus Biotechnology, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
PERCEPTIVE ADVISORS LLC2026-06-30$21.8m11,634,211Reduced−960,000
a16z Capital Management, L.L.C.2026-06-30$16.9m9,063,054Reduced−8,590,863
Cercano Management LLC2026-06-30$13.4m7,172,985Unchanged
BlackRock, Inc.2026-06-30$5.0m2,687,226Added+2,499,555
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$4.8m2,549,979Added+4,382
Comprehensive Financial Management LLC2026-06-30$4.1m2,207,619Unchanged
CITADEL ADVISORS LLC2026-06-30$3.5m1,896,192New+1,896,192
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$2.4m1,265,535Added+662,011
Clearstead Advisors, LLC2026-06-30$1.7m892,787Reduced−1,436,997
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$1.7m890,949New+890,949

Recent filings

All 327 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Nautilus Biotechnology, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2707:37 ET10-QQuarterly reportPeriod 2026-09-300001808805-26-000052
2026-10-2718:46 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001808805-26-000049
2026-09-1117:08 ETSCHEDULE 13D/AOwnership report, active investor, amended0001231919-26-001165
2026-09-1116:08 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits0001808805-26-000041
2026-08-2819:43 ETSCHEDULE 13D/AOwnership report, active investor, amended0001725721-26-000006
2026-08-1417:20 ETSCHEDULE 13D/AOwnership report, active investor, amended0001193125-26-352644
2026-07-2816:06 ET10-QQuarterly reportPeriod 2026-06-300001808805-26-000034
2026-07-2819:29 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001808805-26-000030
2026-06-3017:13 ETSCHEDULE 13D/AOwnership report, active investor, amended0001725721-26-000004
2026-06-1816:05 ET8-K5.07 Shareholder vote results0001808805-26-000027

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures.See the target

About the filer

CIK
1808805
Tickers
NAUT
Exchange
Nasdaq
SIC code
3826 Laboratory Analytical Instruments
Sector
Technology
Fiscal year ends
Dec 31
Incorporated in
not reported
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
ARYA Sciences Acquisition Corp III (to 2021-06-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:43 ET. Listed shows no prices and gives no investment advice.